Ventricular assist devices and increased blood product utilization for cardiac transplantation

  • Matthew L. Stone
  • , Damien J. Lapar
  • , Ehsan Benrashid
  • , David C. Scalzo
  • , Gorav Ailawadi
  • , Irving L. Kron
  • , James D. Bergin
  • , Randal S. Blank
  • , John A. Kern

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Background and Aim of Study The purpose of this study was to examine whether blood product utilization, one-year cell-mediated rejection rates, and mid-term survival significantly differ for ventricular assist device (VAD patients compared to non-VAD (NVAD) patients following cardiac transplantation. Methods From July 2004 to August 2011, 79 patients underwent cardiac transplantation at a single institution. Following exclusion of patients bridged to transplantation with VADs other than the HeartMate II® LVAD (n-=-10), patients were stratified by VAD presence at transplantation: VAD patients (n-=-35, age: 54.0 [48.0-59.0] years) vs. NVAD patients (n-=-34, age: 52.5 [42.8-59.3] years). The primary outcomes of interest were blood product transfusion requirements, one-year cell-mediated rejection rates, and mid-term survival post-transplantation. Results Preoperative patient characteristics were similar for VAD and NVAD patients. NVAD patients presented with higher median preoperative creatinine levels compared to VAD patients (1.3 [1.1-1.6] vs. 1.1 [0.9-1.4], p-=-0.004). VAD patients accrued higher intraoperative transfusion of all blood products (all p-≤-0.001) compared to NVAD patients. The incidence of clinically significant cell-mediated rejection within the first posttransplant year was higher in VAD compared to NVAD patients (66.7% vs. 33.3%, p-=-0.02). During a median follow-up period of 3.2 (2.0, 6.3) years, VAD patients demonstrated an increased postoperative mortality that did not reach statistical significance (20.0% vs. 8.8%, p-=-0.20). Conclusions During the initial era as a bridge to transplantation, the HeartMate II® LVAD significantly increased blood product utilization and one-year cell-mediated rejection rates for cardiac transplantation. Further study is warranted to optimize anticoagulation strategies and to define causal relationships between these factors for the current era of cardiac transplantation. doi: 10.1111/jocs.12474

Original languageEnglish (US)
Pages (from-to)194-200
Number of pages7
JournalJournal of Cardiac Surgery
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2015

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Ventricular assist devices and increased blood product utilization for cardiac transplantation'. Together they form a unique fingerprint.

Cite this